Oncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer Patients
December 02 2015 - 7:00AM
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical
company dedicated to the development of therapeutic products that
can improve the lives and outcomes of patients with cancer, today
announced that it will conduct a conference call on Tuesday,
December 8, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to
discuss new clinical data from ongoing clinical trials of ONT-380,
an orally active, reversible and selective small-molecule HER2
inhibitor being developed for the treatment of metastatic breast
cancer. The data, which include additional and updated
clinical trial data on ONT-380 for the treatment of patients with
HER2-positive metastatic breast cancer, as well as an analysis of
patients who suffer from central nervous system (CNS) metastases,
are slated for presentation during the San Antonio Breast Cancer
Symposium (SABCS) being held December 8-12, 2015 in San Antonio,
TX.
To participate in the call by telephone, please dial (877)
280-7291 (United States) or (707) 287-9361 (International).
In addition, the call will be webcast live and can be accessed on
the "Events" page of the "News & Events" section of
Oncothyreon’s website at www.oncothyreon.com. An archive of the
webcast will be available after completion of the discussion and
will be posted on the Oncothyreon website.
About OncothyreonOncothyreon is a
clinical-stage biopharmaceutical company specializing in the
development of innovative therapeutic products for the treatment of
cancer. Our goal is to discover, develop and commercialize novel
compounds that have the potential to improve the lives and outcomes
of cancer patients. For more information, visit
www.oncothyreon.com.
CONTACT:
Investor Relations:
Julie Rathbun
Rathbun Communications
206-769-9219
ir@oncothyreon.com
Media Relations:
Kelly France, Ph.D.
BrewLife
415-946-1076
kfrance@brewlife.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Apr 2024 to May 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Cascadian Therapeutics, Inc. (delisted) (NASDAQ): 0 recent articles
More News Articles